SCHEMBL3779376

SCHEMBL3779376

COc1ccc(-c2ccc(N3CCN(CC(=O)N4CCN(C5CCC5)CC4)CC3)nn2)cc1C

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HRH3 Q9Y5N1 3/20 0.46
MAPK1 P28482 3/20 0.42
ALDH1A1 P00352 3/20 0.42
HPGD P15428 2/20 0.42
POLB P06746 1/20 0.42
HSD17B10 Q99714 3/20 0.42
TSHR P16473 1/20 0.42
MAPT P10636 1/20 0.41
RAB9A P51151 2/20 0.40
TP53 P04637 2/20 0.39
KDM4E B2RXH2 2/20 0.39
NPC1 O15118 1/20 0.39
CASP1 P29466 1/20 0.39
CASP7 P55210 1/20 0.39
TDP1 Q9NUW8 1/20 0.39
PKM P14618 1/20 0.39
NPSR1 Q6W5P4 1/20 0.39
AURKA O14965 1/20 0.38
GRM5 P41594 1/20 0.38
ALOX15 P16050 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3767484 0.93 MAPK1 (0.49) HRH3MAPK1ALDH1A1HPGDPOLB
SCHEMBL3774746 0.91 LMNA (0.46) HRH3MAPK1ALDH1A1HPGDPOLB
SCHEMBL3763255 0.90 HRH3 (0.43) HRH3MAPTRAB9ATP53NPC1
SCHEMBL3803432 0.88 ALDH1A1 (0.48) HRH3MAPK1ALDH1A1HPGDPOLB
SCHEMBL3776104 0.88 GRM5 (0.49) HRH3GRM5
SCHEMBL3771180 0.87 HRH3 (0.42) HRH3MAPK1ALDH1A1POLBHSD17B10
SCHEMBL3770163 0.87 HRH3 (0.49) HRH3MAPK1ALDH1A1HPGDHSD17B10
SCHEMBL3767881 0.86 HRH3 (0.47) HRH3MAPK1ALDH1A1TSHRMAPT
SCHEMBL3776229 0.86 HRH3 (0.46) HRH3MAPK1ALDH1A1HPGDHSD17B10
SCHEMBL3780493 0.86 GRM5 (0.41) HRH3MAPTNPSR1GRM5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7851474-B2 Dipiperazinyl ketones and related analogues NEUROGEN CORPORATION (US) 2010-12-14 US disclosed
US-7851474-B2 Dipiperazinyl ketones and related analogues NEUROGEN CORPORATION (US) 2010-12-14 US disclosed
US-7851474-B2 Dipiperazinyl ketones and related analogues NEUROGEN CORPORATION (US) 2010-12-14 US disclosed
US-20070049571-A1 Dipiperazinyl ketones and related analogues NEUROGEN CORPORATION 2007-03-01 US disclosed
US-20070049571-A1 Dipiperazinyl ketones and related analogues NEUROGEN CORPORATION 2007-03-01 US disclosed
US-20070049571-A1 Dipiperazinyl ketones and related analogues NEUROGEN CORPORATION 2007-03-01 US disclosed
WO-2007016496-A2 DIPIPERAZINYL KETONES AND RELATED ANALOGUES NEUROGEN CORPORATION (US) 2007-02-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070049571-A1 Dipiperazinyl ketones and related analogues HRH4, HRH3, HRH1 HRH3 2/4885MAPK1 3915/4885ALDH1A1 1210/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.